Contents
Issue 158 • September 2025
In association with
In Depth
Biopharma take on the ADC challenge
The next wave of obesity drugs
Synthetic rescue: Insmed explores a new frontier in genetic therapeutics
Ovarian cancer: why synthetic iMSCs could change the paradigm
New US-EU trade deal on tariffs ends pharma’s geopolitical immunity
Tariff uncertainty a disincentive for US pharma onshoring
Uncertainty remains over FDA ruling on CGT trial samples
Cell and gene therapies on course correction but not sinking